Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma.

The journal of allergy and clinical immunology. In practice - 1 Mar 2023

Kritikos Vicky, Harvey Erin S, Stevens Sean, Katelaris Constance H, Langton David, Rimmer Janet, Farah Claude S, Gillman Andrew, Hew Mark, Radhakrishna Naghmeh, Thomas Dennis, Gibson Peter G

Abstract excerpt

BACKGROUND: Comorbidities in severe asthma are common and contribute to disease burden. The severe asthma phenotype and treatment response can be impacted by comorbid conditions. Real-world data on the use of mepolizumab in severe eosinophilic asthma (SEA) in the presence of comorbidities are needed to inform clinical practice. OBJECTIVE: To investigate the impact of comorbid conditions on baseline phenotype in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Cortex Hormones
Share to Anti-Asthmatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Asthma

Share to Australia

Share to Comorbidity

Share to Nasal Polyps

Share to Obesity

Share to Treatment Outcome

Source

Identifiers

PMID: 36572182
DOI: 10.1016/j.jaip.2022.12.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma.PMID 36572182Read ↗

Effectiveness of mepolizumab in a real-life cohort of patients with severe refractory eosinophilic asthma and multiple comorbiditiesSemantic proximity Read ↗

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity Read ↗

Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.Semantic proximity Read ↗

Clinical Phenotypes of Nasal Polyps and Comorbid Asthma Based on Cluster Analysis of Disease History.Semantic proximity Read ↗

Biologics in severe asthma: the overlap endotype - opportunities and challenges.Semantic proximity Read ↗

Mepolizumab for eosinophilic COPD with frequent exacerbations: single-centre real-world experience in a phenotype-directed approach.Semantic proximity Read ↗

Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic PhenotypeSemantic proximity Read ↗

Real-world sinonasal outcomes in patients with primary diffuse chronic rhinosinusitis treated with mepolizumab across polyp phenotypes.Semantic proximity Read ↗

Heterogeneity of asthma with nasal polyposis phenotypes: A cluster analysis.Semantic proximity Read ↗

Phenotypes and Clinical Outcomes of Omalizumab and Mepolizumab treated Difficult Asthma patientsSemantic proximity Read ↗

Eosinophilic phenotypes of airway disease.Semantic proximity Read ↗

Management of Severe Asthma before Referral to the Severe Asthma Specialist.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.